TW202302642A - 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 - Google Patents

用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 Download PDF

Info

Publication number
TW202302642A
TW202302642A TW111106934A TW111106934A TW202302642A TW 202302642 A TW202302642 A TW 202302642A TW 111106934 A TW111106934 A TW 111106934A TW 111106934 A TW111106934 A TW 111106934A TW 202302642 A TW202302642 A TW 202302642A
Authority
TW
Taiwan
Prior art keywords
antibody
antibody fragment
fragment
cdata
antibodies
Prior art date
Application number
TW111106934A
Other languages
English (en)
Chinese (zh)
Inventor
斯特凡 斯泰德爾
斯特凡 哈特勒
雷納 博克斯哈默
Original Assignee
德商莫菲西斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商莫菲西斯公司 filed Critical 德商莫菲西斯公司
Publication of TW202302642A publication Critical patent/TW202302642A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW111106934A 2021-03-01 2022-02-25 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 TW202302642A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21159860 2021-03-01
EP21159860.2 2021-03-01

Publications (1)

Publication Number Publication Date
TW202302642A true TW202302642A (zh) 2023-01-16

Family

ID=74844778

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111106934A TW202302642A (zh) 2021-03-01 2022-02-25 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體

Country Status (12)

Country Link
US (1) US20240228654A9 (cg-RX-API-DMAC10.html)
EP (1) EP4301779A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024507986A (cg-RX-API-DMAC10.html)
KR (1) KR20230154239A (cg-RX-API-DMAC10.html)
AU (1) AU2022230717A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023016352A2 (cg-RX-API-DMAC10.html)
CA (1) CA3209172A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023002495A1 (cg-RX-API-DMAC10.html)
IL (1) IL304692A (cg-RX-API-DMAC10.html)
MX (1) MX2023009868A (cg-RX-API-DMAC10.html)
TW (1) TW202302642A (cg-RX-API-DMAC10.html)
WO (1) WO2022184676A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202545561A (zh) * 2024-01-16 2025-12-01 德商莫菲西斯有限責任公司 抗體的高度濃縮液體製劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
EP3313441B1 (en) 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
WO2020185672A1 (en) 2019-03-08 2020-09-17 Cedars-Sinai Medical Center Anti-cd38 agents for desensitization and treatment of antibody-mediated rejection of organ transplants
TWI924633B (zh) 2019-03-15 2026-05-11 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物

Also Published As

Publication number Publication date
WO2022184676A1 (en) 2022-09-09
BR112023016352A2 (pt) 2023-10-03
KR20230154239A (ko) 2023-11-07
IL304692A (en) 2023-09-01
CA3209172A1 (en) 2022-09-09
EP4301779A1 (en) 2024-01-10
US20240228654A9 (en) 2024-07-11
CL2023002495A1 (es) 2023-12-29
US20240132618A1 (en) 2024-04-25
AU2022230717A1 (en) 2023-09-14
JP2024507986A (ja) 2024-02-21
MX2023009868A (es) 2023-08-29

Similar Documents

Publication Publication Date Title
US12121579B2 (en) Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
HK1254289A1 (zh) 调控免疫反应的方法及抗体
CN113574071B (zh) 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
US20250388687A1 (en) Epo receptor agonists and antagonists
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
US20240270840A1 (en) Antibodies against cd112r and uses thereof
JP2026015391A (ja) 抗ｃｄ９４抗体及びその使用方法
US20240109977A1 (en) Anti-cd38 antibodies and their uses
JP2024535053A (ja) Ｖｉｓｔａ抗原結合性分子を使用する、がんの処置および防止
US20240228654A9 (en) Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
TW202321303A (zh) 抗pla2r自體抗體媒介膜性腎病變之治療
JP7475011B2 (ja) Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法
TWI790193B (zh) 調控免疫反應之方法及抗體
CN116635422A (zh) 抗cd38抗体及其用途
CN116997570A (zh) 用于治疗抗体介导的移植排斥的抗cd38抗体
HK40099176A (en) Anti-cd 38 antibodies and their uses
CN113557244A (zh) 预防或治疗移植物抗宿主病(GvHD)的抗CCR7 mAb的用途
CN118451108A (zh) 用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法
WO2026080575A1 (en) Anti-cd38 antibodies and their uses
HK40111402A (en) Novel combinations of antibodies and uses thereof
TW202241511A (zh) 新穎抗體組合及其用途
HK40061358B (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease